All Activity

Marijuana can have a number of effects on people who use it but there are no known instances of someone fatally overdosing from consuming cannabis, federal officials say. “No deaths from overdose of marijuana have been reported,” the Drug Enforcement Administration (DEA) said in a new update to its “Drugs of Abuse” publication for 2026. That said, the agency is cautioning that cannabis’s effects on perception and coordination can cause “serious impairments in learning, associative processes, and psychomotor behavior (driving abilities)” and that long-term use can lead to “physical dependence and withdrawal following discontinuation, as well as psychological addiction or dependence.” The report also notes that “there have been an increasing number of emergency room visits involving marijuana edibles.” On the other hand, however, DEA notes that marijuana use can lead to “merriment, happiness, and even exhilaration at high doses.” While the updated 119-page report’s marijuana section is largely the same as the one in the previous edition published in 2024, it has been revised to note the Trump administration’s move to federally reschedule cannabis as well as to more favorably characterize the growing number of states that are changing their own laws. “Over the last three decades, the majority of U.S. states have legalized the sale and use of marijuana for medical purposes as a matter of state law and have established systems to regulate that activity,” the new edition says. The previous version of the document had said: “Although some states within the United States have allowed the use of marijuana for medicinal purpose, it is the U.S. Food and Drug Administration that has the federal authority to approve drugs for medicinal use in the U.S. To date, FDA has not approved a marketing application for any marijuana product for any clinical indication. Consistent therewith, FDA and DEA have concluded that marijuana has no federally approved medical use for treatment in the U.S. and thus it remains as a Schedule I controlled substance under federal law.” The newly updated report notes that in April of this year, “the U.S. Department of Justice placed drug products containing marijuana that have been approved by the Food and Drug Administration (FDA) in schedule III of the Controlled Substances Act” (CSA). “This regulation applies to marijuana as defined in the CSA, marijuana extracts, delta-9- tetrahydrocannabinol and other compounds derived from the marijuana plant (other than the mature stalks and seeds) that fall outside the definition of hemp, to the extent that any of these are included in an FDA-approved drug product or are subject to a state-issued license to manufacture, distribute, and/or dispense marijuana or products containing marijuana for medical purposes,” it says. The new document also includes an updated table of controlled substances that shows state-licensed medical cannabis now falls under Schedule III of the CSA. Under an action announced by Attorney General Todd Blanche in April, marijuana products regulated by a state medical cannabis license immediately moved from Schedule I of the CSA to Schedule III, as did any marijuana products that are approved by the FDA. A hearing is considering broader cannabis rescheduling, including for recreational products. The post There Are ‘No Deaths From Overdose Of Marijuana,’ DEA Confirms In Updated Report appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

The Food and Drug Administration (FDA) is seeking public input on how to design research on the potential therapeutic benefits of the psychedelic ibogaine. The agency’s request for information (RFI), released on Monday, seeks comments and data in four main areas: General study design, including appropriate patient populations; Dose selection and escalation, including the proposed use of small, sequential dose-ascending groups and a starting dose justified by available data and not exceeding 10 mg/kg; Safety considerations, including monitoring for cardiac and neurologic adverse events and other safeguards for clinical trials; and Ethical and oversight considerations, including informed consent and appropriate independent safety oversight. The RFI comes months after President Donald Trump signed a psychedelics executive order aimed at streamlining research on and access to substances such as ibogaine and psilocybin. “Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches,” Michael Davis, director of FDA’s Center for Drug Evaluation and Research, said. “With ibogaine, there are important scientific questions as well as serious safety concerns. We are seeking high-quality data and input that can help inform clinical research while putting patient safety first.” FDA is seeking public input on the design of early-stage clinical trials involving ibogaine products. https://t.co/LmYspHxYeA We want to hear from the public on dosing, safety monitoring, patient safeguards and trial design. Comment period open for 45 days. pic.twitter.com/LvPt0bDISW — FDA Drugs and Biologics (@FDADrugs) October 5, 2026 A Federal Register notice accompanying the RFI notes that research on ibogaine to date has “significant limitations” and, as such, there is “uncertainty about the benefit-risk profile of ibogaine drug products.” FDA said it is not interested in any comments on legalization or decriminalization of psychedelics, federal scheduling status, religious use or the safety or effectiveness of any specific ibogaine drug product. Broadly, the agency said that information received through the RFI will help it “better understand the potential uses, benefits and risks of ibogaine drug products and inform approaches to drug development.” Comments are being accepted through November 20. The ibogaine RFI comes weeks after FDA hosted a public hearing on psychedelic therapy, with officials taking testimony from dozens of advocates, researchers and industry participants. In July, the agency issued finalized guidance to help researchers studying the therapeutic benefits of psychedelics navigate the “unique challenges” of such investigations. In April, FDA issued national priority vouchers to three companies studying psilocybin for treatment-resistant depression and major depressive disorder, as well as methylone (MDMC) for post-traumatic stress disorder (PTSD), and additionally allowed an early phase clinical study of an ibogaine derivative to proceed with an Investigational New Drug (IND) submission. FDA also signed a memorandum of understanding with the Department of Veterans Affairs (VA) concerning a partnership to collaborate on research and development of psychedelic medicines to treat people struggling with serious mental health conditions. Last week, a bipartisan congressional psychedelics caucus published a report on how substances like psilocybin, ibogaine and DMT can be “safely and ethically integrated” into the U.S. healthcare system, emphasizing the need for collaboration across federal agencies and with states. Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. said in a podcast released last month that he believes there will be an “enormous demand” for psychedelic therapies as they become legally available, and he thinks Trump is unique among his predecessors in championing the issue. FDA and HHS in April announced steps that they say will help with “accelerating” therapeutic access to psychedelics for patients dealing with serious mental health conditions. In August, the Substance Abuse and Mental Health Services Administration issued a report on recent advances in psychedelic medicine, along with recommendations for state policymakers on how to prepare for formal approval of drugs like psilocybin and MDMA. It also noted how the Schedule I status of many psychedelics has hampered scientific studies on their effects for decades. In May, a bipartisan coalition of 32 members of Congress sent a letter urging FDA to expedite ongoing reviews of psychedelic therapies. Lawmakers recently filed a new bill that would require the Department of Defense (DOD) to evaluate how ongoing research on the therapeutic benefits of psilocybin could help members of the military. A separate recently introduced bipartisan measure is intended to codify Trump’s psychedelics executive order into law. An amendment adopted as part of the National Defense Authorization Act would extend a psychedelics research effort at DOD for an additional six years. Photo courtesy of Scamperdale. The post FDA Seeks Public Input On Psychedelic Research Involving Ibogaine appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

You make so many great points here that I read your article a couple of times. Your views are in accordance with my own for the most part. This is great content for your readers. panduan lengkap tentang totosgp

Federal officials say they will prioritize issuing tax-related guidance for marijuana businesses within the next year in light of the Trump administration’s move to federally reschedule cannabis. Moving marijuana from Schedule I of the Controlled Substances Act (CSA) to Schedule III will have large tax implications for cannabis industry operators. That’s because an Internal Revenue Service (IRS) code known as 280E, which has prevented them from taking ordinary tax deductions and credits that are available to most businesses, only applies to Schedule I and II substances. The U.S. Department of the Treasury and IRS said in April that they plan to issue guidance on tax issues for marijuana businesses stemming from rescheduling, but that hasn’t yet happened. But now, Treasury and IRS officials have included the issue in their 2026–2027 Priority Guidance Plan, indicating that they intend to follow through on providing tax clarity for cannabis businesses in the coming months. The document includes “Guidance under §280E” in a list of 121 items officials plan to prioritize over the next year, though it doesn’t provide any additional marijuana-related information beyond that. “Each year, the Treasury Department’s Office of Tax Policy and the IRS use the Guidance Priority List to identify and prioritize that tax issues that should be addressed through regulations, revenue rulings, revenue procedures, notices, and other published administrative guidance,” IRS said. “The Guidance Priority List focuses resources on guidance items that are most important to taxpayers and tax administration. Published guidance plays an important role in increasing voluntary compliance by helping to clarify ambiguous areas of the tax law.” The current plan, released last week, will cover the federal fiscal year that runs from October 1, 2026 to September 30, 2027, but it “does not provide any deadline for completing the projects,” the document says. In May, a group of congressional Democrats sent a latter asking Treasury Secretary Scott Bessent and IRS Chief Executive Officer Frank Bisignano to issue “prompt guidance” on tax issues for marijuana businesses in light of the Trump administration’s move to federally reschedule cannabis. “The absence of clear and timely guidance for the cannabis industry will leave taxpayers uncertain as to how they can benefit from the tax code—whether it is the treatment of ordinary and necessary business deductions or accessing of tax credits,” the lawmakers wrote. In contrast, a pair of Republican lawmakers in June sent a letter to the treasury secretary saying they are “concerned” and “troubled” that marijuana businesses will be eligible for tax relief now that cannabis is being partially rescheduled under federal law. Those lawmakers previously filed legislation called the No Deductions for Marijuana Businesses Act that would continue to prevent the cannabis industry from escaping the 280E penalty even under rescheduling. Under an order issued by Attorney General Todd Blanche in April, marijuana regulated by a state medical cannabis license immediately moved to Schedule III. Marijuana products such as those in state-legal recreational markets remain in Schedule I for now, however, subject to an ongoing hearing process that is considering broader rescheduling of cannabis. In their previous announcement about forthcoming guidance, IRS and Treasury said they “expect DOJ’s action to have significant positive tax consequences for businesses in the medical marijuana industry.” “Accordingly, rescheduling generally removes section 280E as a bar to claiming deductions and credits for businesses that as a result of the Final Order no longer traffic in Schedule I or II controlled substances under the CSA,” they said. Because of the way the rescheduling action is being rolled out in phases, state-licensed marijuana companies that serve both the medical and recreational markets may only be able to immediately obtain tax relief for parts of their businesses. “Guidance is expected to clarify the ways in which, for businesses with multiple activities, section 280E applies only to those activities related to trafficking in Schedule I or II controlled substances (e.g., by apportioning expenses),” the tax agency and Treasury Department said. Blanche’s rescheduling order for DOJ said he “encourages” the treasury secretary “to consider providing retrospective relief from Section 280E liability for taxable years in which a state licensee operated under a state medical marijuana license.” But the Treasury and IRS announcement said that, at least for an initial transition rule, “rescheduling generally will be considered to first apply for a business’s full taxable year that includes the effective date of the Final Order, for the business’s activities that do not involve Schedule I or II controlled substances as a result of the Final Order.” The post Federal Officials Say Marijuana Industry Tax Guidance Will Be A ‘Priority’ For The Next Year appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

NY hits $4 billion in marijuana sales; VA medical cannabis patient survey; Study: Medical marijuana for autism; NC public cannabis use policy Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… Hold on, just one second before you read today’s news. Have you thought about giving some financial support to Marijuana Moment? If so, today would be a great day to contribute. We’re planning our reporting for the coming months and it would really help to know what kind of support we can count on. Check us out on Patreon and sign up to give $25/month today: https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Florida activists filed two new marijuana legalization initiatives for the 2028 ballot, a development that comes as a third previously submitted measure to legalize cannabis is also still pending. The New York Office of Cannabis Management reported that retailers in the state have now sold more than $4 billion worth of recreational marijuana products since the market launched—including nearly $1.5 billion so far this year alone. The Virginia Cannabis Control Authority is asking medical marijuana patients to complete a “satisfaction survey” about the state’s program—including questions about how the launch of recreational sales will impact them. A new study conducted by the Minnesota Office of Cannabis Management found that people with autism who use medical marijuana “were able to achieve and maintain symptom relief” for anxiety, depression and sleep. “Medical cannabis patients qualified for ASD reported reduced anxiety and a sub-set of patients reported reduced presence/severity of behavioral symptoms after starting medical cannabis.” The North Carolina Advisory Council on Cannabis is weighing proposed recommendations on how the state should address public use of marijuana if it moves forward with legalization. Oregon hemp retailers and suppliers are worried that changes to federal laws stand to put them out of business. “The CBD products that people are expecting to be available to give to their dogs for arthritis or to give to their parents because they’re aging and have aches and pains that are helped by some of these cannabinoids, they’re not going to have access to them anymore.” CannaShark Consulting’s Adrian A. Holguin offers advice in a new op-ed for Missouri marijuana microbusiness license applicants on how to avoid getting scammed when signing contracts and deals. / FEDERAL The Government Accountability Office published a report with recommendations on how the Department of Justice and Department of Homeland Security can better collaborate on counternarcotics investigations. Sen. Pete Ricketts (R-NE) tweeted, “Communist China dominates marijuana markets in America. Its criminal organizations exploit our land, traffic foreign workers, and use prohibited chemicals to produce cannabis. These illicit drug enterprises threaten our communities and national security.” The Congressional Research Service published an updated report on hemp issues. / STATES A New Jersey senator is being sued by his former chief of staff for allegedly recruiting people to serve as social equity ‘owners’ of marijuana businesses that they did not actually control. Virginia hemp businesses are asking to withdraw a lawsuit they filed challenging new state product restrictions, saying they plan to refile it in revised form. Colorado regulators sent an update about adverse health reports linked to cannabis vape products. Connecticut regulators published guidance about changes to marijuana laws that took effect this month. Missouri regulators published guidance about testing requirements for ingestible cannabis concentrates. Illinois regulators published annual cannabis reports. Minnesota’s Cannabis Expungement Board is seeking a new executive director. New York regulators approved a new research license to study whether a cannabis-based medicine could provide relief for people with chronic pain. Michigan regulators revoked a marijuana business’s license and issued a fine over alleged violations. Oregon regulators will consider changes to hemp product registration rules on October 21. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL Trinidad and Tobago lawmakers approved a bill making changes to cannabis, alcohol, tobacco and gambling laws. Israeli officials are considering limiting the scope of an investigation into Canadian medical cannabis being “dumped” into the country’s market. / SCIENCE & HEALTH A review concluded that the endocannabinoid system “is a promising therapeutic target for endometriosis-associated pain, as it regulates nociception, inflammation, and proliferation.” A study suggested that “C. sativa hairy root-derived nanovesicles represent a stable immunomodulatory platform with potential applications in cancer immunotherapy and other diseases requiring enhanced cellular immune responses.” / ADVOCACY, OPINION & ANALYSIS The National Rifle Association, Second Amendment Foundation and Firearms Policy Coalition filed an amicus brief urging the Supreme Court to take up a case challenging the federal government’s permanent denial of gun rights to a man over a marijuana cultivation conviction. / BUSINESS Curaleaf International received the first approval from Australian officials for a device intended for the delivery of cannabis extracts via inhalation. AYR Wellness Inc. completed the first transfer of its Ohio operations into wholly-owned subsidiaries of Arboretum Bidco LLC. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post New push to put cannabis on Florida’s ballot (Newsletter: October 5, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“The most important protection for Missouri’s newest cannabis entrepreneurs may not be another rule. It may be knowing when not to sign.” By Adrian A. Holguin, CannaShark Consulting via Missouri Independent Missouri drew its final round of marijuana microbusiness applicants on September 9. The state received 888 applications and expects to issue approximately 77 licenses beginning in December. I want to write about the months in between, because I work in the trade that operates in them. I am a consultant. I run licensing, compliance and operations work for cannabis operators, and I have sat across the table from first-time licensees more times than I can count. When the state put new microbusiness rules in place in May, I did not read them as an attack on the trade. I read them as rules aimed at the right problem that stop just short of solving it. The rules are good ones. They spell out what it means to majority-own and operate a license. They let regulators review ownership arrangements before a license issues rather than after, which is the change that should have come first. They require a compliance course before applying and again after the award. And they require eligible owners to serve as the primary point of contact with regulators during the application process, limiting one of the ways consultants can make themselves indispensable. All of that reaches the contract. None of it reaches the wait. Consider what a top-drawn applicant actually holds this fall: the prospect of a license coming as soon as December, a facility they may not have secured, capital they may not have raised and no experience operating in a regulated industry. Forty-six licenses from the first two rounds are active but not yet approved to operate. As of August 18, only 21 microbusinesses were operating. Jimi Poe, who won in the first round and became the first to open a microbusiness dispensary, told the division’s own podcast it took him two years rather than the six months he expected. That is the exposure. Not necessarily a bad clause. It is a long, unfunded, inexperienced wait, during which somebody will offer to carry it for you. A wait does two things to a person. It drains cash and it makes them feel behind, and both push toward signing. The offer usually arrives sounding like relief: We will fund the build-out. We will handle compliance. We will run it until you are ready. Some of those offers are honest. Others can look just as reassuring on the first read, which is precisely the problem. Most people who sign a bad agreement are not careless. They are outmatched. The licensee has never done this before and the person across the table may have done it dozens of times. So let me be useful rather than righteous, and name some things licensees should watch for when dealing with people in my own industry. Watch for equity that vests on signature rather than on delivery. Ask why an adviser is receiving ownership before the promised work has been completed, and whether that equity could instead be tied to specific milestones. Watch for a management agreement wearing a consulting label. If the document hands someone else hiring authority, banking authority or control of the seed-to-sale account, that is not simply advice. Under the new rules, those kinds of provisions could also raise questions about whether eligible owners retain the control Missouri now requires. Watch for fees calculated against gross rather than net. A percentage of revenue does not care whether the operator ever makes money. Watch for standard operating procedures that do not describe your building. Everyone starts from a template. But if the document refers to rooms you do not have, nobody walked your facility closely enough. And ask the question that sorts this trade quickly: Which licensees have you taken from award to operation, and may I speak with them? A consultant with a successful track record should be able to provide references. Lesley Turek, the division’s chief equity officer, has already offered another safeguard. She has advised current and future licensees to run proposed arrangements or agreements past the division so regulators can identify potential compliance problems. That is an open door, offered by the regulator, and in my experience new licensees do not always walk through it because asking feels like admitting you do not know. That reading is backwards. Running a draft agreement past your own regulator is among the cheapest diligence available in this industry, and it costs nothing. The state spent this cycle making the paperwork harder to abuse, which was the right move. What regulation cannot eliminate is the vulnerability created during the months when a new licensee has something worth taking and little experience defending it. That is why the most important protection for Missouri’s newest cannabis entrepreneurs may not be another rule. It may be knowing when not to sign. Adrian A. Holguin is founder and president of CannaShark Consulting, a national consulting firm based in California that handles licensing, compliance and operations for cannabis operators. This piece was first published by Missouri Independent. The post Advice For Missouri Marijuana Microbusinesses On How Not To Get Scammed When Signing Contracts (Op-Ed) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“The CBD products that people are expecting to be available to give to their dogs for arthritis or to give to their parents because they’re aging and have aches…they’re not going to have access to them anymore.” By Mia Maldonado, Oregon Capital Chronicle Pet tinctures and topicals are the most popular products sold at Oregon CBD Company, a small business located at the junction of the Willamette Valley town’s busiest roads. Pet owners use them to treat their pets’ anxiety or pain—and in some cases they use similar products to treat their own. Those products used to line most of the store’s shelves. Now, those shelves are empty as the store plans to close by the end of this month in response to a federal law that will ban most of the products it sells by the end of the year. Muscle rubs, aromatherapy soaps and body washes make up the majority of what’s left in the store. A “for rent” sign sits outside of the building while buy-one, get-one-free flyers sit on top of the store’s mostly empty tables. The other half of the building, Oregon Cannabis Company, is a dispensary under the same owner that will remain open. The difference between the two stores’ products is that one sells items made from hemp, and the other, from marijuana. Hemp and marijuana are from the same plant species, but hemp has much lower levels of tetrahydrocannabinol, or THC—the psychoactive component of the plant that provides a “high” feeling among marijuana users. Hemp is most commonly used for its nonimpairing chemical compound cannabidiol, known as CBD. “The easiest way to explain CBD is that it is like a healthier version of ibuprofen,” store manager Leslie Frost told the Capital Chronicle from behind a cash register and an empty display case. Before becoming manager, Frost was taking 1,200 milligrams of ibuprofen a day to manage chronic migraines and pain from a knee surgery before turning to CBD products. For the past few years, she’s helped a growing number of Oregonians, particularly the elderly, with similar experiences find products that work for them. Frost and her coworkers aren’t out of a job or losing hours because there’s still enough business coming in through the company’s dispensary side. The biggest hit to the business will be the loss of its customers who bought CBD products for their pets, Frost said. Federal changes target unintended hemp loophole Amid the country’s longest government shutdown in late 2025, Sen. Mitch McConnell, a Kentucky Republican, added an amendment to a government funding bill dramatically narrowing the definition of hemp. The law repeals the very law McConnell championed in 2018 when he introduced a Farm Bill that legalized the cultivation of hemp plants with a THC concentration of 0.3 percent or lower by dry weight. The law was meant to allow an agricultural market for hemp-based textiles, animal feeds and human wellness products centered on CBD products. The new hemp law closes an unintended legal loophole of the 2018 law that opened the door for hemp manufacturers to convert legal hemp plants into potent forms of synthetic marijuana, Stateline reported. The law bans the sale of any “hemp-derived cannabinoid product” with more than 0.4 milligrams of total THC per container, which is most hemp-derived products such as edibles, tinctures and beverages. It was set to take effect in November, but Congress pushed its effective date to December 11. ‘They’re not going to have access anymore’: Hemp seed farmer talks federal changes “The law essentially ends the hemp industry,” said Seth Crawford, the co-owner of Oregon CBD Seeds, an Independence-based company that supplies 75 percent of the hemp seed grown in the country. Crawford and other farmers can continue to grow hemp under the new federal law, but he said he doesn’t anticipate he’ll have as many people buying seeds since there won’t be as many processors that can make hemp-derived products that meet the new guidelines Crawford and his brother started their hemp seed business in 2014, shortly after Oregon legalized recreational marijuana. Noticing the potential market for hemp-based products, Crawford, who has a public policy background, and his brother, who has a horticulture background, teamed up to create a hemp seed farm as well as an internationally leading cannabis research lab. Their 50-acre farm off Oregon Highway 99W is home to several greenhouses, dozens of grow tents, solar panels and millions of dollars worth of research equipment used to understand the genetic structure of hemp varieties. Their business was recovering from a years-long decline in sales following the pandemic when Congress passed the law. Unless Congress finds a fix, which several Democratic members have tried, Crawford said his plan is to focus on selling hemp seeds to home growers. “I can kind of understand why it has been swept under the rug while we’re worrying about whether or not we’re going to have free and open elections in November,” Crawford said. Part of Crawford’s interest in medical cannabis grew out of taking care of his dog, a yellow lab named Berkley, who had arthritis in his hips. Crawford would make him a CBD oil that he would put into a cookie and feed it to him. It gave him nearly four extra years of mobility towards the end of his life and it helped him during seizures, he said. “The CBD products that people are expecting to be available to give to their dogs for arthritis or to give to their parents because they’re aging and have aches and pains that are helped by some of these cannabinoids, they’re not going to have access to them anymore,” he said. This story was first published by Oregon Capital Chronicle. The post Federal Changes Will Put Hemp Industry Operators Out Of Business, Oregon Retailers And Suppliers Say appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

“We want the public to understand exactly what this means. We don’t want to have to have law enforcement try to guess at businesses, are they public or are they private?” By Clayton Henkel, NC Newsline North Carolina’s Advisory Council on Cannabis faces a December 31 deadline to issue final recommendations for a comprehensive cannabis policy to Gov. Josh Stein (D). While the legislature would have to agree to enact any changes in existing law, the council gave the public its first glimpse this week of how a public consumption policy might be crafted. Anne Doyle and Kaycee Deen with the state Division of Public Health told council members that cannabis consumption needs its own framework of policies, because it doesn’t fit neatly within state laws governing alcohol or tobacco use. To establish a cannabis-specific policy, Doyle said her team has examined how other states have opted to regulate public consumption. In Virginia, retail sales of recreational cannabis begin July 1, 2027, but it will be illegal to smoke it in public. Lawmakers there are already considering increasing the civil penalty for public use from $25 to $250. In California, smoking or ingesting cannabis in public is prohibited, but they do allow for its use in designated lounges or cafes. Colorado likewise bans open products and public consumption but allows for local exceptions in hospitality spaces. Across all those states, Doyle said the baseline is that legal possession does not mean that you have the right to use or consume cannabis in public. Defining public spaces Deen said after many conversations with policymakers and public safety officials in other states, they drafted five recommendations for THC consumption in North Carolina. The first recommendation prohibits the consumption of all THC products in any public place. Public spaces could be broadly defined to cover restaurants and bars, beaches, parks, event venues and public buildings. “The goal is to make the rule very intuitive,” said Deen. “We want the public to understand exactly what this means. We don’t want to have to have law enforcement try to guess at businesses, are they public or are they private?” The recommendation becomes trickier when it comes to housing. A homeowner would be free to consume cannabis in their private residence, but different rules might apply for renters. “The landlord who owns the home makes a decision that that home should be smoke-free. You do have to abide by that,” said Deen. Deen said other states advised North Carolina to avoid relying on “private event” labels that could turn a public business into a consumption site. “Let’s say a famous pop star decides to rent out the Lenovo Center for her wedding. If we had an exception for a private event, they would be able to allow smoking during that event while it was rented out privately,” Deen explained. Another policy choice to consider would be a narrow exception for THC beverages, Deen said. “You could allow licensed restaurants to be able to sell THC beverages for on premises consumption only, not to be taken off the property,” said Deen. “They would be like a menu item similar to mixed drinks or beer wine.” Deen said restaurants are a very controlled environment, where staff could be trained on THC products, and they would have 21 plus ID verification. “They have limits on serving sizes and THC per serving,” she said. “Another thing that we’ve learned from the alcohol space is that a way to limit consumption is to raise the price.” The second draft recommendation would prohibit consumption of THC in a moving vehicle by drivers and passengers. An open THC container in the passenger area would also be prohibited. The vehicle rule would not require impairment to be enforceable. Narrowing consumption locations A third proposed recommendation would be to not allow dedicated consumption lounges. “It’s always easier to restrict something at the beginning and then open up those laws later,” Deen advised. “They complicate enforcement.” A fourth draft recommendation is to preserve authority for private housing to further restrict these cannabis consumption laws. This would be a safeguard for HOAs or condominium associations. Deen said spelling this out in the initial policy could help prevent a lot of litigation. Forrest Parker, CEO of Qualla Enterprises and Great Smoky Cannabis Company, said people are looking for safe places to consume cannabis, which is legal for recreational use on Cherokee land in North Carolina. While the concept of cannabis lounges may not have worked financially in other states, Parker said they recognize consumer demand. “We’re actually starting to slightly explore whether it makes sense for us to provide a safe place,” Parker said. Parker said with a larger portion of their customers being visitors, many are looking for a place they can legally use cannabis when Cherokee hotels, casinos and other public spaces remain off limits. “We have a lot of campgrounds actually beginning to promote a ‘420 friendly’ vacation model,” Parker said. “They’re closing off certain sections of the campground and building barriers so that children don’t have easy access. Really responsible.” Recreational cannabis is legal for adults over 21 on tribal land, but upon leaving the Qualla boundary, individuals are subject to North Carolina state laws. A pushback on civil fines The final draft recommendation would use civil infractions, or fines, as the default enforcement mechanism for the public consumption rules. “Just like it was when they enacted the smoke-free restaurants and bars, they got a lot of complaints at the beginning for several years. Then they got less and less,” said Deen. “There was a behavior change.” Doyle said this is another area where North Carolina can borrow from other states. “California does not impose infractions or fines on minors. They actually require education,” said Doyle. “That could be a really interesting thing to think about [instead of] punishment.” Roxboro Police Chief David Hess said the wording on enforcement recommendations needed work. “If what I’m carrying out of this recommendation is for law enforcement to go around issuing civil fines for public consumption, we’re going to erode public trust,” Hess said. Hess said in North Carolina municipal law enforcement doesn’t have the statutory authority to enforce civil laws. That’s a function of sheriffs’ departments, he said. “You would be entering local law enforcement into a new space that historically has never been permitted in North Carolina. That’s going to come with a significant amount of training,” Hess said. Col. Freddy Johnson, commander of the North Carolina Highway Patrol, agreed with Hess, but thought many of the state’s open-container laws for alcohol could be adapted to work for cannabis consumption. Other advisory members indicated they would be agreeable to allowing bars and restaurants to continue to sell THC-infused beverages. “If we did have legal products, the legislature could limit the amount that you can put in a container, a can, or bottle. Many states have done that,” said Dr. Larry Greenblatt, state health director and co-chair of the advisory council. Greenblatt said the draft recommendations should be considered a work in progress. Subcommittees will be meeting throughout October and November where the guardrails will be fine-tuned. Even after the final report is delivered to the governor, the General Assembly would need to agree on the legislation. Attempts to legalize medical marijuana have died in the state House in recent years, despite support from some senior Senate leaders. The Trump administration has called on the U.S. Department of Justice to reclassify marijuana as a Schedule III drug, the same class as Tylenol. This story was first published by NC Newsline. Photo courtesy of Martin Alonso. The post North Carolina Advisory Panel Weighs Cannabis Public Use Policies As Part Of Recommendation To Governor appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

I’m going to read this. I’ll be sure to come back. thanks for sharing. and also This article gives the light in which we can observe the reality. this is very nice one and gives indepth information. thanks for this nice article... situs togel online

This particular papers fabulous, and My spouse and i enjoy each of the perform that you have placed into this. I’m sure that you will be making a really useful place. I has been additionally pleased. Good perform! sengtoto slot gacor

New York’s recreational marijuana dispensaries have now sold more than $4 billion worth of legal cannabis products, state officials have announced. The Office of Cannabis Management (OCM) revealed the sales totals at a Cannabis Control Board (CCB) meeting on Thursday. The $4.1 billion worth of adult-use marijuana products since sales began in late 2022 includes almost $1.5 billion so far in 2026 alone. Third quarter sales reached $512.6 million, bringing the total for this year to date to $1.41 billion. The OCM update also noted that a significant share of the state’s legal cannabis market is comprised of social and economic equity businesses, and that almost two-thirds (64 percent) of new licenses issued at Thursday’s meeting meet that designation. CCB this week also approved a new cannabis nursery license application window and extended the provisional license period for equity and provisional marijuana business licenses. “Today’s actions are about opening doors, helping businesses move forward, and protecting the integrity of New York’s cannabis market,” Jessica García, chair of the CCB, said in a press release. According to OCM, the state currently has 1,981 licensed adult-use marijuana businesses, including: 280 cultivators 241 distributors 329 microbusinesses 582 processors 548 retail dispensaries 370 Conditional Adult-Use Retail Dispensaries Fifty-six percent of all recreational cannabis business licenses have been awarded to social and economic equity applicants. “That representation across the supply chain is meaningful progress, and our work is to make sure these businesses have the support to grow and thrive,” L. Simone Washington, OCM’s chief equity officer, said. Separately, Gov. Kathy Hochul (D) recently signed legislation clarifying that marijuana microbusinesses can fully participate in cannabis farmers’ markets and pop-up events. In May, OCM began accepting applications from licensed dispensaries that want to host temporary cannabis farmers’ markets and pop-up events. The launch of applications this year followed the enactment of earlier legislation signed by Hochul last year that built on an existing showcase program that was first created in 2023. The state Cannabis Control Board (CCB) adopted regulations for the events program that is now rolling out last May. In March, the governor marked the five-year anniversary of adult-use marijuana legalization in New York, highlighting $3.3 billion in retail sales at that point, the opening of more than 600 licensed cannabis shops and achievements in promoting social equity in the industry while taking steps to mitigate the illicit market. In January, New York officials released a set of reports providing a 2025 end-of-year status update on the evolution of the state’s medical and adult-use marijuana markets—touting record sales, revenue hauls for state coffers, licensing approvals, equity initiatives and more. The OCM annual report also notes that Hochul signed legislation into law that expands the state’s medical cannabis program by improving patient access and “updating the program framework to better meet patient needs statewide.” Meanwhile, a coalition of New York marijuana businesses are asking the governor to veto legislation that would create a new Cannabis Wage Board charged with recommending minimum hourly wages for industry workers. The proposal would “create significant uncertainty for operators at a time when many are finally beginning to find their footing after years of regulatory delays, capital constraints, and continued competition from the illicit market,” an action alert sent by the Cannabis Association of New York (CANY) said. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Separately, New York senators recently approved a bill related to reciprocity for out-of-state medical marijuana patients and the availability of pre-rolled joints in the medical cannabis market—even though the state has already enacted those reforms separately. In February, the sponsor of the bill separately introduced legislation that would allow New York liquor and wine stores to obtain a permit to sell low-dose cannabis-infused drinks at their businesses. Also, the governor recently signed legislation into law that revises zoning requirements for licensed marijuana businesses, granting more flexibility to retailers located within certain distances of schools and places of worship. The post New York Dispensaries Have Sold More Than $4 Billion In Recreational Marijuana Since The Market Launched, State Officials Announce appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Florida activists submitted two new proposed marijuana legalization ballot initiatives to state officials this week. The first measure, from a group called Floridians for Marijuana, would allow adults over the age of 21 to legally use cannabis. They could possess up to two ounces of marijuana, including no more than five grams of cannabis concentrates. Existing medical cannabis dispensaries would be able to sell recreational marijuana to adults as of the effective date, which would be six months after approval by voters. New businesses would also be allowed to acquire, cultivate, process, transport and or sell marijuana to adults for personal use. Unlike current medical cannabis businesses, however, there would be no requirement for them to be vertically integrated. The measure specifies that marketing and packaging of marijuana in a manner attractive to children would be prohibited, as would smoking or vaping cannabis in any public place. Owners of private property would maintain the right to prohibit marijuana use on premises. It also says that prior to the effective date, lawmakers will need to adopt legislation concerning marijuana business licensing and to regulate the time, place and manner of the public consumption of cannabis. “Nothing herein shall prohibit the legislature from providing for the home growing of marijuana by adults for their personal use and the reasonable regulation thereof,” it says. “Nothing herein shall limit the right of the legislature, subject to Section 19 of Article VII of this Constitution, to exercise its authority through general law in providing for the taxation of sales of marijuana and appropriating such tax revenues to fund law enforcement, education, or as otherwise determined by the Legislature.” The second new initiative, filed by an organization called Let Florida Vote IV, is similar but contains additional provisions contemplating the designation of a separate agency to license marijuana businesses beyond the Department of Health, which currently oversees medical cannabis. It states that existing medical marijuana treatment centers and licensed marijuana entities could acquire cannabis from, and sell or transfer it to one another. The measure directs the legislature to pass a bill to provide for the issuance of cannabis business licenses “to any applicant meeting reasonable and objective qualifications” and specifies that there cannot be fees “in excess of the reasonable cost of administration and enforcement.” If lawmakers do not pass such a law by the effective date, the Department of Health would then promulgate rules for marijuana business licensure within six months and then begin issuing licenses within nine months of the effective date, it says. The separate committees behind the two new initiatives have the same chair and treasurer. Let Florida Vote IV has a website where people can request a copy of the petition be mailed to them to sign. Meanwhile, also still pending is a marijuana legalization ballot measure from Smart & Safe Florida, a campaign committee whose earlier measure on the 2024 ballot got majority support but fell short of the 60 percent threshold needed to pass a constitutional amendment in Florida. The group also tried to get cannabis legalization on Florida’s 2026 ballot but fell short after state officials invalidated tens of thousands of signatures. For any of the three currently pending marijuana legalization measures to make the 2028 ballot, organizers will need to submit 880,062 valid signatures from registered voters. Along the way, submission of 220,016 valid signatures will trigger a judicial and financial impact review from state officials. The post Recreational Marijuana Would Be Legalized In Florida Under Two Newly Filed Ballot Measures appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Virginia regulators are asking patients to complete a “satisfaction survey” about the state’s medical marijuana program. The Virginia Cannabis Control Authority (CCA) said the questionnaire is designed to help officials “hear from the people who know Virginia’s medical cannabis program firsthand.” The survey includes questions about how often patients use medical marijuana, what types of products they consume and where they obtain it from—including whether they go to retailers in other states. Responses will help CCA have a “better understanding of the patient experience and help identify opportunities to strengthen the program,” the agency said, noting that last year more than 114,000 individual patients purchased medical cannabis from a licensed dispensary in Virginia. “Patients bring an important perspective to the medical cannabis program because they experience it firsthand,” Jamie Patten, CCA’s acting head and chief administrative officer, said in a press release. “We want to make sure we are listening to that perspective and using what we learn to make meaningful improvements.” The survey asks patients about what conditions they use medical marijuana for and how much money they typically spend on it, as well as when and how they obtained a medical cannabis recommendation and whether it was from a healthcare provider they regularly see or if it was via a one-time appointment. CCA also wants to know how long it takes patients to travel to dispensaries and what factors go into their purchasing decisions, such as price, potency, packaging design, staff recommendations, strain type and delivery availability. The survey additionally asks patients how strongly they agree or disagree with a number of statements, including: Virginia medical dispensaries offer the types of products I want to purchase. I trust the safety of products available in legal dispensaries in Virginia. Dispensary employees are knowledgeable of the products they sell. Medical cannabis in Virginia is easily accessible for me. The Virginia Cannabis Control Authority is responsive to patient inquiries and requests for information. The pharmacist on duty at the medical cannabis dispensary is helpful in figuring out the best products for my condition. The pharmacist or other staff always inform me of potential adverse reactions I could experience when taking medical cannabis. The cost of my medical cannabis is reasonable. Medical cannabis has improved my diagnosed medical condition(s)/symptom(s). Medical cannabis has reduced my need for prescription drugs for pain reduction. I would recommend the Virginia medical cannabis program to a friend or family member. Notably, CCA is also asking patients about their thoughts on the forthcoming system of legal and regulated recreational marijuana sales that lawmakers and the governor approved this year. What, if anything, concerns you about the introduction of an adult-use retail marijuana market in Virginia as it relates to your current medical cannabis use? What, if anything, excites you about the introduction of an adult-use retail marijuana market in Virginia as it relates to your current medical cannabis use? When adult-use marijuana becomes available in Virginia, how do you expect your cannabis purchasing to change? I will continue using the medical cannabis program only. I will continue using the medical cannabis program and purchase from adult-use retail stores. Unsure The agency’s press release noted that a prior medical cannabis patient survey in 2024 resulted in a recommendation to expand training and education for health care providers, which CCA implemented. Officials are asking patients to complete the current survey by October 16. Earlier this year, CCA launched a separate survey to gather input from the public and stakeholders about implementation of the state’s newly enacted law legalizing recreational cannabis sales. Meanwhile, lawmakers passed and the governor signed several other reform bills this session—including measures to provide resentencing relief for people with past cannabis convictions, protect the parental rights of marijuana consumers and allow patients to access medical cannabis in hospitals. The post Virginia Officials Launch Medical Marijuana Patient Survey, Including Questions About How Recreational Legalization Will Impact Them appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Medical marijuana helps people with autism ease their anxiety and depression, according a new study conducted by state officials in Minnesota. The research, which involved 1,800 patients enrolled in the state’s medical marijuana program, is “one of the largest on record involving autism spectrum disorder (ASD) and medical cannabis patients,” officials said. Of the 88 percent of patients who reported experiencing moderate to severe anxiety upon entering the program, more than half (57 percent) were able to reduce their anxiety by 30 percent or more within four months of beginning medical cannabis use, and 67 percent of those maintained that reduction for an additional four months, according to their answers on self-report surveys. “Patients also reported similar improvements in disturbed sleep (37.3%), fatigue (34.4%), and depression (41.3%) scores,” the study said. “In summary, a proportion of patients qualified for ASD report to have reached clinically meaningful improvements in various symptoms, some of which are commonly reported in this population such as anxiety, depression, and sleep disturbances,” it concluded. “Patients were able to achieve and maintain symptom relief after starting medical cannabis.” The study also compiled quotes from patients and caregivers about the benefits they saw from medical marijuana: “Medical cannabis has helped me deal with so many aspects of my disorder. From being able to eat food in the morning without being sick to being an addition to therapy and the like.” “It feels like my autistic anxiety has calmed down a bit. It helps me sleep a little better. Numbs the depression pain a little.” “[Patient] seems happier, smiles more and will engage in an activity more easily.” “Decrease in anxiety, decrease in aggressive behavior, decrease in self-injurious behavior, sleeping much better, decrease in seizures, better appetite.” “Medical cannabis has eased social anxiety as well as anxiety that I have in the workplace. It has allowed me to be a better student, friend and employee to my peers.” “This study demonstrates the value of listening to patients and using real-world data to better understand how medical cannabis may improve their quality of life,” OCM Executive Director Eric Taubel said in a press release. “The findings are encouraging, particularly for patients experiencing anxiety, depression, sleep difficulties and other conditions that can accompany autism. As Minnesota’s cannabis market continues to evolve, research like this helps us build a stronger evidence base and make informed decisions that put patients and public health first.” “Medical cannabis patients qualified for ASD reported reduced anxiety and a sub-set of patients reported reduced presence/severity of behavioral symptoms after starting medical cannabis.” The researchers cautioned that there are some limitations to the study, however. For example, since all patients involved used medical marijuana, it “cannot compare the effectiveness in symptom relief to a control or placebo group.” Other limitations are that there was a lack of information about what other medications and treatments the patients were using, and that many patients were under the age of 18 and had a parent or caregiver filling out the surveys for them. Daren Howard, interim executive director of the Autism Society of Minnesota, said the group is”particularly encouraged by findings that medical cannabis patients with autism report reduced anxiety and depression, because these are pervasive concerns within our community.” “This study represents an important step toward safely informing the public and expanding access to supportive treatment options,” he said. A previous study published by state officials in Minnesota found that medical cannabis appears to help cancer patients by decreasing pain, nausea, vomiting, anxiety and depression while also improving sleep. Another study they conducted showed that medical marijuana use by chronic pain patients is associated with significant improvements in life enjoyment, general activity and physical wellbeing. OCM also conducted a study showing that medical cannabis provides significant benefits for people struggling with sleep apnea. Last month, Minnesota officials touted the fact that retailers have sold more than a quarter of a billion dollars’ worth in legal marijuana products since the state’s legal recreational cannabis market launched one year ago. Photo courtesy of Carlos Gracia. The post Medical Marijuana Helps People With Autism Reduce Anxiety And Depression, Government Study Shows appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Congressional psychedelics report; GA medical marijuana delivery; CA gov signs cannabis edibles & drinks bill; Vets medical marijuana research measure Subscribe to receive Marijuana Moment’s newsletter in your inbox every weekday morning. It’s the best way to make sure you know which cannabis stories are shaping the day. Get our daily newsletter. Email address: Leave this field empty if you're human: Your support makes Marijuana Moment possible… BREAKING: Journalism is often consumed for free, but costs money to produce! While this newsletter is proudly sent without cost to you, our ability to send it each day depends on the financial support of readers who can afford to give it. So if you’ve got a few dollars to spare each month and believe in the work we do, please consider joining us on Patreon today. https://www.patreon.com/marijuanamoment / TOP THINGS TO KNOW Sen. Tom Cotton (R-AR) and three other Republican senators sent a letter asking Attorney General Todd Blanche to “investigate the growing role of Chinese transnational criminal organizations in America’s cannabis and intoxicating-hemp markets.” “Chinese transnational criminal organizations dominate marijuana cultivation and distribution in the United States, especially in states with legal cannabis markets.” The Congressional Psychedelics Advancing Therapies Caucus published a report highlighting the need for collaboration across federal agencies and with states to accelerate safe access to therapeutic use of substances like psilocybin and ibogaine. Reps. Lou Correa (D-CA) and Jack Bergman (D-CA) filed a bill directing the Department of Veterans Affairs to study the benefits of medical cannabis for military veterans with PTSD and chronic pain. The Georgia Access to Medical Cannabis Commission approved new rules allowing medical marijuana delivery, including via the U.S. Postal Service (USPS) and private carriers like FedEx and UPS—but the federal agency is refusing to clarify if it will take part in cannabis commerce. California Gov. Gavin Newsom (D) signed a bill adding new packaging and labeling rules for marijuana-infused edibles and beverages, as well as a requirement that retailers offer consumers measuring instruments or devices for cannabis drinks with more than one serving. A new Maryland law that took effect on Thursday allows firefighters and rescue workers to use medical cannabis while off duty without being punished for it. / FEDERAL A federal judge ordered the Department of Justice to provide an Office of Legal Counsel memo that supposedly provides justification for the Trump administration’s military strikes on suspected drug boats. Department of Health and Human Services Deputy General Counsel Matt Zorn spoke about efforts to ensure that psychedelic treatments are “available” and “affordable.” / STATES The Tennessee Senate Judiciary Committee held hearings on a medical cannabis legalization bill. Florida House Democrats are asking the Internal Revenue Service to investigate whether the use of Medicaid funding to campaign against a marijuana legalization ballot initiative was property reported and whether taxes are due. Here’s a look at where North Carolina Senate and House candidates stand on marijuana and hemp issues. Missouri regulators filed proposed changes to marijuana business rules. Maryland regulators are launching a cannabinoid proficiency testing pilot study comparing five laboratories. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — / INTERNATIONAL The European Food Safety Authority issued a positive opinion on the use of CBD in foods. / SCIENCE & HEALTH A review concluded that “cannabinoids exhibit biologically plausible antitumour activity across multiple cancer hallmarks and may present promising candidates for combination therapeutic strategies.” A study found that “psilocybin and LSD use may promote positive environmental attitudes, which could, in turn, be associated with a greater likelihood of adopting a vegetarian diet.” / ADVOCACY, OPINION & ANALYSIS The American Trade Association for Cannabis and Hemp published a report finding that a lack of consistent moisture standards for cannabis costs companies and state governments tens of millions of dollars every year and exposes consumers to lower-quality and potentially unsafe products. / BUSINESS Metrc commissioned a study that found consumers support putting state-issued QR codes on cannabis products to provide access to lab testing results, compliance data and safety resources. Curaleaf Holdings, Inc. touted that it has raised and donated more than $600,000 combined for Breast Cancer Action Month causes over the last seven years. Make sure to subscribe to get Marijuana Moment’s daily dispatch in your inbox. Get our daily newsletter. Email address: Leave this field empty if you're human: Photo courtesy of Chris Wallis // Side Pocket Images. The post GOP senators push probe on cannabis & China ties (Newsletter: October 2, 2026) appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Delhi Escorts !! Delhi Escort !! Delhi Escorts Service !! Delhi Escorts Agency !! Escorts Service In Delhi !! Call Girls in Delhi !! Escort Service In Delhi !! Delhi Call Girls !! Escorts In Delhi !! Independent Escort Service In Delhi !! Delhi Call Girl Service !! Escort Service In Delhi !! Delhi Escort Service !! Delhi Call Girl !!

Top Female Escorts in Delhi are waiting for you to make an intimate Fun Welcome to Female Escorts in Delhi, your trusted source for booking sophisticated and exclusive escorts in Delhi with ease. We’ve simplified the reservation process to help you enjoy spontaneity and moments of excitement without any hassle. Our responsive and knowledgeable support team, available around the clock via phone, WhatsApp, and Telegram, is just a quick message away to assist you. Share essential details such as the name of your preferred Delhi escort, desired date and time, and chosen meeting location for a seamless booking experience. Whether you're a local resident or a visitor seeking unforgettable companionship services in the city, we're here to guide you every step of the way. For further information or assistance, feel free to reach out to us or complete the form provided. Flexible Booking for Escorts in Delhi Our agency boasts an extensive portfolio of over 200 exceptional escorts, offering unmatched availability for both short-notice engagements and advanced reservations. Whether you're in search of a spur-of-the-moment encounter or planning an upcoming meeting, our Escorts in Delhi are ready to provide unforgettable experiences tailored to your desires. Browse our comprehensive gallery to find your perfect match among Delhi Escorts. Variety of Escorts to Suit Every Preference Our agency features an impressive selection of escorts in Delhi, each with distinct charisma and personality to meet diverse needs. Whether you seek the approachable charm of the girl next door or the sophistication of an international model, we offer companions for any occasion or mood. Delhi ESCORT !! Delhi ESCORTS SERVICE !! Delhi FEMALE ESCORT SERVICE !! ESCORTS IN Delhi !! Delhi CALL GIRLS !! Delhi INDEPENDENT ESCORTS SERVICE !! INDEPENDENT Delhi ESCORTS !! ESCORT SERVICE Delhi !! CALL GIRLS SERVICE Delhi !! Delhi ESCORTS !! Delhi ESCORTS AGENCY !! ESCORTS SERVICE IN Delhi !! CALL GIRLS IN Delhi !! MODEL ESCORTS CALL GIRLS !! Delhi INDEPENDENT ESCORTS !! FEMALE ESCORTS SERVICE !! INDEPENDENT ESCORTS SERVICE IN Delhi

This peptide calculator can be a helpful addition to your list of online tools for peptide calculations:

Players looking for cool and creative usernames can find plenty of nama ff keren ideas on this page:

This is a handy resource for finding cross symbols copy and paste options when you want to add decorative characters to your online content:

Bipartisan congressional lawmakers introduced a bill to direct the U.S. Department of Veterans Affairs (VA) to carry out studies on the therapeutic potential of marijuana for military veterans with certain conditions. An earlier Senate version of the VA medical cannabis legislation cleared a committee in that chamber and was taken up on the floor for action but was blocked from advancing by Republicans. Under the proposal as reintroduced for the current Congress on Thursday by Reps. Lou Correa (D-CA) and Jack Bergman (R-MI), VA would be tasked with conducting studies that explore the effects of cannabis for veterans with post-traumatic stress disorder (PTSD) and chronic pain. “With the opioid crisis raging across America, it is imperative to the health and safety of our veterans that we find alternative treatments for chronic pain and service-related injuries,” Correa said in a press release. “Throughout my district, I consistently meet veterans who depend on cannabis to manage their pain. Numerous veterans attest to the treatment benefits of medical cannabis. It’s time the VA did a formal study and began recognizing that cannabis can play a safe role in our veterans’ healthcare.” Bergman said that “veterans struggling with PTSD and chronic pain deserve access to treatments backed by sound science and rigorous research.” “The VA Medicinal Cannabis Research Act will help us better understand whether medicinal cannabis can provide safe and effective relief while ensuring Veterans’ health and safety remain the top priority,” he said. “We owe it to our veterans to explore every responsible avenue that could improve their quality of life.” A change to the version of the bill that was filed last Congress as compared to initial iterations, which has also carried over to the new measure, would give VA greater latitude in determining for itself whether it’s capable of overseeing clinical trials into marijuana for chronic pain and PTSD. That appeared to be responsive to concerns expressed by VA officials who testified against the earlier proposals. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — A previous version of the legislation cleared a House committee in 2021, despite the protests of VA officials. Earlier iterations of the measure also moved through committee in 2020 and 2018 as well, but none were enacted into law. The current legislation includes a requirement for a retroactive observation study to look into the experiences of veterans who’ve used marijuana for such treatment in the past outside of the clinical trail context. Within 90 days of completion of an observational study on the effects of cannabis on PTSD and chronic pain, VA would be required to submit a report to Congress on whether it’s capable of carrying out the more robust clinical trials that were at the center of earlier forms of the legislation. “The Secretary may terminate the clinical trials…if the Secretary determines that the Department of Veterans Affairs is unable to meet clinical guideline requirements necessary to conduct such trials or the clinical trials would create excessive risk to participant,” the bill text says. VA has repeatedly come out against past versions of the reform proposal, with the department suggesting that the research mandate goes too far with too many requirements. Under the current language, the department could finish the qualitative observational study and then independently decide against carrying out the clinical trial portion involving human subjects. Other revisions in the most recent prior version that carried over to the current measure as compared to those filed in past years include removing language that required studies to involve at least seven cannabis varieties and instead leaving that open-ended. “The VFW supports the VA Medicinal Cannabis Research Act,” Pat Murray, director of national legislative service for Veterans of Foreign Wars (VFW), said. “VFW members tell us that medicinal cannabis has helped them cope with chronic pain and other service-connected health conditions. They cannot receive these services at VA because of VA’s bureaucratic hurdles. “VA uses evidence-based clinical guidelines to manage other pharmacological treatments of post-traumatic stress disorder, chronic pain, and substance use disorder because medical trials have found them effective,” Murray said. “VA must expand research on the efficacy of non-traditional medical therapies, such as medicinal cannabis and other holistic approaches.” Kyleanne Hunter, CEO of Iraq and Afghanistan Veterans of America (IAVA), said that the group’s members “have said consistently and passionately that cannabis offers real help with the most pressing injuries we face when we come home, from chronic pain to PTSD to traumatic brain injury.” “Our national policies are lagging, research is lacking, and the stigma persists,” Hunter said, “The VA Medicinal Cannabis Research Act is how we start to change that. Every solution begins with research, and veterans have waited long enough for it.” The post VA Would Be Required To Study Medical Marijuana’s Benefits For Veterans With PTSD And Pain Under New Congressional Bill appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Este artigo sobre símbolos despertou bastante minha curiosidade. É interessante descobrir como diferentes símbolos podem transmitir ideias e significados distintos. Para continuar pesquisando sobre o tema, recomendo

If you're exploring different delta executor resources, this page is worth taking a look at. I found the information clear and convenient to access:

A new Maryland law that took effect this week will protect firefighters and rescue workers from being penalized over their lawful use of medical marijuana off the job. Gov. Wes Moore (D) gave final approval to the measure in April after it cleared the Senate and House of Delegates, and it officially became operative on Thursday. The new policy, which was sponsored by Sen. Carl Jackson (D), amends the state’s medical marijuana law by stipulating that firefighters, emergency medical technicians, cardiac rescue technicians and paramedics employed by the state or local governments will not face employment discrimination or retaliation for testing positive for cannabis metabolites if they’re a registered patient. As of October 1, employers cannot “discipline, discharge, or otherwise discriminate against the fire and rescue public safety employee with respect to the employee’s compensation, terms, conditions, or privileges of employment” if they test positive while holding a medical cannabis registration. Further, employers cannot “limit, segregate, or classify its employees in any way that would deprive or tend to deprive the fire and rescue public safety employee of employment opportunities or otherwise adversely affect the fire and rescue public safety employee’s status as an employee.” Nothing in the legislation prohibits employers from taking action against an employee for showing up to work while under the influence of cannabis, and any instances where a public safety worker is found to be impaired while on duty will be reported to the State Emergency Medical Services Board. The enactment of SB 439 comes after years of attempts over recent sessions to enact the reform aimed at giving emergency service professionals the option to use cannabis as an alternative treatment for health conditions that commonly afflict the first responder community. Del. Adrian Boafo (D) sponsored an identical bill, HB 797, that passed the House this session. The change is “so critically important to our firefighters” and other rescue professionals who “work long shifts in tense emergencies and high-stress situations every day,” Boafo said at a committee hearing. “Many experience chronic pain, injuries and anxiety as a direct result of serving our communities,” the lawmaker said. “Medical cannabis, when prescribed and used off duty, can help manage those conditions. But under current policies, firefighters who use medically prescribed cannabis can face retaliation or discipline from their employers, even when they’re following the law.” “That leaves many of these public servants with a difficult choice: Either continue doing their jobs in pain, or turn to stronger prescription drug drugs, often opiates, just to get through the day,” Boafo said, while emphasizing that “nothing in this bill allows for impairment on the job” and that those who come to work impaired “will still face serious consequences and will be reported” to state emergency medical services regulators. “Public safety remains a top priority here in Maryland, but our state must modernize its laws to protect employees who use medically certified cannabis responsibly and outside of the workplace,” he said. “Our firefighters and rescue professionals dedicate their lives to protecting us. They should not be punished for seeking legal, medically prescribed relief for the physical toll of that work.” The enactment of the House and Senate cannabis bills comes a year after officials in Maryland’s most populous county said they were moving to loosen marijuana policies for would-be police officers in an effort to boost recruitment amid a staffing shortage. — Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments. Learn more about our marijuana bill tracker and become a supporter on Patreon to get access. — Also taking effect this week is a new Maryland law providing legal protections for veterinarians who recommend medical cannabis for animals. Another proposal that Moore signed this session extends a psychedelics task force through the end of 2027 to develop updated recommendations on expanding therapeutic access to the novel drugs and potentially creating a regulatory framework for broader legalization. Legislators also took up a bill this session to protect the gun rights of medical marijuana patients in the state, but it did not pass. Photo courtesy of Brian Shamblen. The post Maryland Firefighters And Rescue Workers Can Now Use Medical Marijuana Off Duty Without Being Punished For It appeared first on Marijuana Moment. View the live link on MarijuanaMoment.net

Las letras bonitas permiten crear combinaciones originales para frases, nombres y contenido de redes sociales. Prueba distintas opciones en